Kin Meds Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.5/10
Best for: oral orforglipron alongside the injectables
Kin Meds falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the monthly price
Medication
Not stated
Clinician visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Kin Meds starts compounded semaglutide at $199/mo and compounded tirzepatide at $249/mo, and carries brand-name FDA-approved options including Wegovy injection and pill, Zepbound and Foundayo from $149/mo. It is LegitScript-verified. Beyond weight loss the account also covers Sermorelin, NAD+, glutathione, TRT, hair, skin and sexual health, so members can run several protocols in one place.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Kin Meds
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Kin Meds at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide, Wegovy, Zepbound
- Starting price
- $146/mo ($53 off first order, applied automatically at checkout per kinmeds.com/glp1-discount ('Save $53 on first order -Disco...)
- FDA status
- 1 FDA warning letter on record — see below
How Kin Meds scores
Six columns, each one computed from something Kin Meds has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
5.0/10$149/month is exactly the register median for brand orforglipron.
Effectiveness25%
10.0/10Dispenses orforglipron and semaglutide and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
3.5/101 FDA warning letter on record; does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Kin Meds
Last checked August 2026- Re-read the price on file across 5 dose or plan tiers
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with Kin Meds involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Kin Meds publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Kin Meds does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- Cheapest standing monthly prices on record: orforglipron $149. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether Kin Meds serves your state cannot be confirmed from its site.
- 1 FDA warning letter on record. The letter itself is linked in the enforcement section below — read what it alleges rather than the fact that it exists.
Kin Meds support, as documented
- Phone
- +1 410-457-9875
- Hours
- Mon-Fri 9:00am-5:00pm; Sat-Sun closed
GLP-1 medications Kin Meds offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Peptides Kin Meds offers
Kin Meds sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.
Pricing
Prices re-verified
$53 off first order, applied automatically at checkout per kinmeds.com/glp1-discount ('Save $53 on first order -Discount applied at checkout')
$53 off first order, auto-applied; discount page quotes starting dose 'as low as $49/week' first month
Entry pricing — likely insured/savings-card tier; cash-pay NovoCare standard pen is $299/mo (oral pill $149)
Entry pricing — likely insured/savings-card tier; cash-pay LillyDirect vials run $299-$449/mo
Matches the LillyDirect $149/mo starter cash price for Foundayo
Check the price yourself before you pay
Every figure here was read off Kin Meds's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Orforglipron at $149 a month, within the normal band around this register's $149 median for the same drug and form
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Kin Meds charges
The figure Kin Meds leads with is $146, and it is a first-month rate. From month two the price is $149/month, which is the number to plan around. Nothing improper about an introductory offer — it just is not the price of staying on the medication.
- Compounded semaglutide — $146 first month, then $199/month
- Compounded tirzepatide — $196 first month, then $249/month
- Brand-name semaglutide — $149/month
- Brand-name tirzepatide — $149/month
- Brand-name orforglipron — $149/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so Kin Meds is genuinely under the middle rather than merely advertising that it is.
Found, at about $149/month, is the closest thing we track to a like-for-like alternative.
What Kin Meds dispenses
Kin Meds prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. Both routes are available: the FDA-approved pen, or a compounded version at lower cost. The distinction is not cosmetic — the approved product has been reviewed for safety, efficacy and manufacturing quality, and a compounded preparation has not.
What we could verify
Kin Meds publishes little that can be checked from outside an intake. FDA has sent this operator a warning letter, and we flag it at the top of the page. A letter is a disclosure, not a disqualification: read what it actually says before deciding what it means for you. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You would be choosing on the advertised figure. The introductory month is real, but it is not what you will be paying in month three.
- You need to bill insurance. Like most of this market, this is cash-pay.
- A regulatory record matters to you more than price does — read the warning letter flagged above before deciding.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want a cheap way to find out whether the medication suits you before committing
Our read
Kin Meds is a cheap way to start and an ordinary way to continue. Use the $146 month for what it is good for — establishing whether the medication works for you — and re-run the numbers against $149/month before you let it renew twice. Whatever you decide, read the warning letter flagged at the top of this page first, and raise it with the clinician you would be prescribing through.
The Bottom Line
Kin Meds falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Kin Meds
Starting at $149/month. Check today's price, then book the free consultation.
Where Kin Meds is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
Kin Meds has an FDA warning letter on record, dated February 20, 2026
This letter concerns false & misleading claims/misbranded. A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this Kin Meds review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Kin Meds's current pricing
Plans start at $149/month. The free consultation is where you learn whether you qualify, and what it costs today.